Optimal subsite occupancy and design of a selective inhibitor of urokinase.
about
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinaseThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingPhage-displayed peptide libraries.Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate librariesEngineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage.Substrate specificity of the Escherichia coli outer membrane protease OmpT.Phage display substrate: a blind method for determining protease specificity.Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites.Anthrax toxin: structures, functions and tumour targeting.Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.Small Molecule Active Site Directed Tools for Studying Human CaspasesPlatelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progressionDissecting the urokinase activation pathway using urokinase-activated anthrax toxin.The efficiency of dentin sialoprotein-phosphophoryn processing is affected by mutations both flanking and distant from the cleavage siteSelection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.Urokinase plasminogen activator system as a potential target for cancer therapy.Urokinase-controlled tumor penetrating peptide.Tripeptides with non-code amino acids as potential serine proteases inhibitors.Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.Revisiting catalysis by chymotrypsin family serine proteases using peptide substrates and inhibitors with unnatural main chains.Synthesis and Biological Activity of N-Sulfonyltripeptides with C-Terminal Arginine as Potential Serine Proteases Inhibitors.Protease-sensitive fluorescent nanofibers.Comparative binding energy analysis for binding affinity and target selectivity prediction.Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator.
P2860
Q24531982-53C89042-BE3F-4341-9252-B2529ECE460EQ27622497-B378881A-4110-4624-92A7-6BDB3D8747EBQ28257803-E7EAE7AF-3831-4F90-94BA-F65ACDD4B987Q30431344-D0B913B5-98D8-4929-A5C1-BC12E0F056F3Q30882677-E6048375-D1CA-4200-9217-50BF0DC8289DQ30905453-099F0F5E-3EEF-454B-A949-0E9767246E76Q31106776-C2109C5E-5026-47FD-9ADF-F590EE0B0DBEQ31118897-AB234B8D-F193-4D01-A19C-EAE747538517Q33518855-D20A58BE-BD61-4C76-A0F4-652B4AA7A003Q35126550-EB1F49CC-CF67-4B92-9012-ED32301FEF92Q35184740-7033FB0A-5F9A-41B0-9B31-AF904A29F7E2Q35783096-832E8127-7A13-4F86-BE27-CF7AB53A3E75Q35836079-FCD8F778-0956-4B59-A44A-E8136311B811Q35929823-D3AF0C4A-0F86-4CBF-B098-15D0137D36E2Q36086826-D8D405BE-761E-4D1A-8F75-6B0C030AB908Q36636043-7910CF3D-57D8-4774-A73E-C10B08BDF945Q36864660-C83C33DA-7361-4D34-8639-C65DDC3B5AA3Q37630593-877E84C6-6C8B-4AC6-A9B4-0E5E30246255Q37712358-F34F896B-75B7-4056-ACAD-F3E27174A636Q39402728-F2A8D695-7B01-43AE-A65F-ECBB697D4B73Q40839885-D8F394DE-0D7B-43BF-B32B-2F32FBB74766Q41685096-1E6D751E-E2DE-45A9-BF03-C81883D504C8Q42062362-E59C09C0-F9BC-4F6E-910F-6152B4252256Q42425220-57576F8D-55E4-41D5-BB78-B282EA9F2FBAQ43273730-86A135BD-3F98-4DC5-9DFD-3D8684B9D114Q43705156-ED6EF9A1-2905-4251-97DE-1079A2FE0747Q44779601-A3DFBD3C-24AF-4D48-BEF1-E1B2999B71F4Q47293918-A871F1DA-3F41-46F8-8C09-2B913EF4E8B6
P2860
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@en
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@nl
type
label
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@en
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@nl
prefLabel
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@en
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@nl
P2093
P2860
P356
P1476
Optimal subsite occupancy and design of a selective inhibitor of urokinase.
@en
P2093
P2860
P304
20456-20462
P356
10.1074/JBC.272.33.20456
P407
P577
1997-08-01T00:00:00Z